Document is current
Any future updates will be listed below
-
Authors
Papinska, Anna
Viswanathan, Lakshmi
Lu, Qiang
Abane, Farida
Psoinos, Charles
Ruiz-Soto, Rodrigo
-
Funding
Funding for this research was provided by:
Deciphera Pharmaceuticals
- License Information
-
More Information
Article History
Received: 31 January 2025
Accepted: 2 July 2025
First Online: 20 July 2025
Declarations
:
: Anna Papinska reports employment with Deciphera Pharmaceuticals, LLC (self). Lakshmi Viswanathan reports employment with Deciphera Pharmaceuticals, LLC (self). Qiang Lu reports employment with Deciphera Pharmaceuticals, LLC (self). Farida Abane reports employment with Deciphera Pharmaceuticals, LLC (self). Charles Psoinos reports employment with Deciphera Pharmaceuticals, LLC (self). Rodrigo Ruiz-Soto was employed by and reported royalties from Deciphera Pharmaceuticals, LLC at the time the research was conducted (self). As of October 2024, Rodrigo Ruiz-Soto is affiliated with AntibodyChem Biosciences (Newton, MA, USA).
: All methods and procedures were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Guidelines for Good Clinical Practice. The protocol was approved by the IRB IntegReview and by the FDA. According to FDAAA Sect. 801, Final Rule (42 CFR Part 11), phase 1 trials are not considered applicable clinical trials requiring registration in a public registry. As a phase 1 clinical trial conducted only in the USA, this trial was not registered on ClinicalTrials.gov. All individuals provided written informed consent prior to enrollment.
